

U.S. Serial No. 09/425,516

8

Group Art Unit 1644

63 121. A method for inhibiting cytokine production by a T cell comprising contacting the T cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23, thereby inhibiting cytokine production by the T cell.

REMARKS

Applicants thank Examiner Gambel for the courtesy of the telephonic interviews conducted on February 6 and February 7 and are grateful for his suggested claim amendments.

Claims 28, 65-67 and 70-72 were pending in the application. Claims 28, and 65-67 have been canceled without prejudice herein. Upon entry of this amendment, claims 70-121 will be pending. Applicants' amendment and/or cancellation of claims should in no way be construed as an acquiescence to the Examiner's position with respect to the claims as previously pending. Applicants reserve the right to further prosecute the same or similar claims in a subsequent patent application.

No new matter has been added by way of these amendments. Support for the above claim amendments can be found in the application as filed and/or the claims as previously pending. Specifically, support for "blocking binding interactions of B7-2 with CD28 or CTLA4" can be found at least at page 7. Support for "inhibiting proliferation of a T cell" and "inhibiting cytokine production by a T cell" can be found at least at page 38. Support for "downregulating an immune response" can be found at least at page 40. Support for "prophylactically" and "therapeutically" modulating an immune response can be found at least at page 7. Support for "polyclonal" and "monoclonal" can be found at least at page 33. Support for "chimeric" and "humanized" can be found at least at page 35. Support for "human" antibody can be found at least at page 36. Support for "F(ab')₂" or "Fab" can be found at least at page 34. Support for

U.S. Serial No. 09/425,516

9

Group Art Unit 1644

"ATCC accession number HB 11688," "ATCC accession number HB 11687," and "ATCC accession number HB 11686" can be found at least at page 34. Support for "contacting the cell with an additional immunosuppressive agent," "anti-B7-1 antibody" and "immunosuppressive drug" can be found at least in claim 68 as previously pending.

A version of the amendments showing changes made is attached as Appendix A.

SUMMARY

If a telephone conversation with Applicants' attorney would expedite the prosecution of the above-identified application, the examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: February 10, 2003

U.S. Serial No. 09/425,516

10

Group Art Unit 1644

VERSION SHOWING CHANGES MADE

- 70. The method of claim [28] 73, wherein the step of contacting is performed in vitro.
- 71. The method of claim [28] 73, wherein the step of contacting is performed in vivo.
- 72. The method of claim [28] 73, wherein the B7-2 is human B7-2.